Company Overview and News

 
UPDATE 1-UK Stocks-Factors to watch on Oct 12

2018-10-12 reuters
Oct 12 - Britain’s FTSE 100 index is seen opening 27 points higher at 7,034 with FTSE 100 futures up 0.51 percent ahead of the cash market open on Friday, according to financial bookmakers.
MNGPF MNGPY ATYM CPG CMPGY EMG AYM CMPGF

 
Swiss stocks - Factors to watch on Oct. 12

2018-10-12 reuters
ZURICH/BERLIN, Oct 12 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Friday:
ATYM BBAGF AYM

 
METALS-London aluminium eyes 4 pct weekly fall, biggest since June

2018-10-12 reuters
MELBOURNE, Oct 12 (Reuters) - London aluminium steadied on Friday after metals were caught in a widespread market sell-off this week and ahead of Chinese trade data later in the session, but it was set for its biggest weekly drop since June as concerns over raw material costs eased.
ATYM AYM

2
Trafigura-backed copper miner Atalaya Mining seeks buyer -sources

2018-10-11 reuters
LONDON, Oct 11 (Reuters) - Copper producer Atalaya Mining , which is backed by Swiss trading giant Trafigura, is looking for a buyer, two banking sources said on Thursday.
RTPPF ATYM RIO RIO RIO RTNTF AYM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:AYM / Atalaya Mining Plc on message board site Silicon Investor.

Raymond L. Dirks Internet Research Tribunal Thread Raymond L. Dirks Internet Research Tribunal Thread Raymond L. Dirks Internet Research Tribunal Thread LML Payments Systems, Inc. (LMLP) LML Payments Systems, Inc. (LMLP) LML Payments Systems, Inc. (LMLP)
Official Payments Corp. (OPAY) Official Payments Corp. (OPAY) Official Payments Corp. (OPAY) XRMD - XRAYMEDIA.COM INC XRMD - XRAYMEDIA.COM INC XRMD - XRAYMEDIA.COM INC
VIAP ViaPay - Global payment and global solutions. VIAP ViaPay - Global payment and global solutions. VIAP ViaPay - Global payment and global solutions. New Claymore Resources New Claymore Resources New Claymore Resources
Xraymedia/Ebidd Xraymedia/Ebidd Xraymedia/Ebidd Maymac MMA-VSE Maymac MMA-VSE Maymac MMA-VSE
Valu-Net Corp (VNE on ASE - was Faymar) Valu-Net Corp (VNE on ASE - was Faymar) Valu-Net Corp (VNE on ASE - was Faymar) Raymor Resources (Alberta Stock Exchange:RAR) Raymor Resources (Alberta Stock Exchange:RAR) Raymor Resources (Alberta Stock Exchange:RAR)